BiotechTube

Evacetrapib + Ezetimibe + Atorvastatin + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesterolemia

Conditions

Hypercholesterolemia

Trial Timeline

Jan 1, 2015 → Nov 1, 2015

NCT ID
NCT02260648

About Evacetrapib + Ezetimibe + Atorvastatin + Placebo

Evacetrapib + Ezetimibe + Atorvastatin + Placebo is a phase 3 stage product being developed by Eli Lilly for Hypercholesterolemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02260648. Target conditions include Hypercholesterolemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02260648Phase 3Terminated

Competing Products

20 competing products in Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
85
Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
85
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
85
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
colesevelam HCl + placeboDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed-dose combination with ezetimibeDaiichi SankyoPre-clinical
23
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Bempedoic Acid 180Mg/Ezetimibe 10Mg TabDaiichi SankyoPre-clinical
23
Colesevelam Hydrochloride + Ezetimibe + SimvastatinDaiichi SankyoApproved
85
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
atrovastatinAstellas PharmaPre-clinical
23
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mgEli LillyApproved
85
PPAR alpha + atorvastatin + placeboEli LillyPhase 2
52
Evacetrapib + PlaceboEli LillyPhase 3
77
LY3015014 + Placebo + Statin + EzetimibeEli LillyPhase 2
52
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 2
52
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85